16 lines
30 KiB
JSON
16 lines
30 KiB
JSON
{
|
||
"issueKey": "{{issue.key}}",
|
||
"summary": "{{issue.fields.summary}}",
|
||
"description": "{{issue.fields.description}}",
|
||
"comment": "{{comment.body}}",
|
||
"labels": "{{issue.fields.labels}}",
|
||
"status": "{{issue.fields.status.name}}",
|
||
"assignee": "{{issue.fields.assignee.displayName}}",
|
||
"updated": "{{issue.fields.updated}}"
|
||
}
|
||
|
||
|
||
RESPONSE
|
||
|
||
|
||
{ "issueKey": "HSM-1235", "summary": "RE: MDM Database Export", "description": "Hi Barbara, As you requested reports we have shared. So, we are closing this ticket. Regards Deepan *From:* Paulraj, Deepanraj *Sent:* Wednesday, July 24, 2024 2:16 PM *To:* Veberič, Barbara <Barbara.Veberic@pfizer.com>; DL-Global MDM Support <DL-Global-MDM-Support@pfizer.com> *Cc:* DL-ATP_MDMHUB_SUPPORT_PROD <DL-ATP_MDMHUB_SUPPORT_PROD@pfizer.com> *Subject:* RE: MDM Database Export Hi Barbara, Please find the attached file. Regards Deepan *From:* Paulraj, Deepanraj *Sent:* Tuesday, July 23, 2024 6:36 PM *To:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]>; DL-Global MDM Support <[DL-Global-MDM-Support@pfizer.com|mailto:DL-Global-MDM-Support@pfizer.com]> *Cc:* DL-ATP_MDMHUB_SUPPORT_PROD <[DL-ATP_MDMHUB_SUPPORT_PROD@pfizer.com|mailto:DL-ATP_MDMHUB_SUPPORT_PROD@pfizer.com]> *Subject:* RE: MDM Database Export Hi [@Veberič, Barbara|mailto:Barbara.Veberic@pfizer.com], Below request is acknowledge with IM ticket no: *IM44430883* Currently, we have started to export these reports, once completed we will share you. Regards Deepan *From:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Sent:* Tuesday, July 23, 2024 4:26 PM *To:* DL-ATP_MDMHUB_SUPPORT_PROD <[DL-ATP_MDMHUB_SUPPORT_PROD@pfizer.com|mailto:DL-ATP_MDMHUB_SUPPORT_PROD@pfizer.com]>; DL-Global MDM Support <[DL-Global-MDM-Support@pfizer.com|mailto:DL-Global-MDM-Support@pfizer.com]> *Subject:* FW: MDM Database Export Dear Colleagues, I was referred to you by [@MANTRI, KOMAL|mailto:KOMAL.MANTRI@pfizer.com]. I'm interested in obtaining an export via MDM that includes *approved speakers per country and their last briefing date.* Specifically, I require data for *all Adriatic countries,* including Slovenia, Croatia, Bosnia, and Serbia. Thank you in advance! Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* MANTRI, KOMAL <[KOMAL.MANTRI@pfizer.com|mailto:KOMAL.MANTRI@pfizer.com]> *Sent:* Tuesday, July 23, 2024 12:50 PM *To:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Subject:* RE: MDM Database Export Hi [@Veberič, Barbara|mailto:Barbara.Veberic@pfizer.com], Thank you for reaching out. However, the below markets are currently not available in Pfizer Reltio. Please reach out to HUB and IQVIA Reltio team for exports. [DL-ATP_MDMHUB_SUPPORT_PROD@pfizer.com/|mailto:DL-ATP_MDMHUB_SUPPORT_PROD@pfizer.com/] [DL-Global-MDM-Support@pfizer.com|mailto:DL-Global-MDM-Support@pfizer.com] Regards, Komal *From:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Sent:* Tuesday, July 23, 2024 4:02 PM *To:* MANTRI, KOMAL <[KOMAL.MANTRI@pfizer.com|mailto:KOMAL.MANTRI@pfizer.com]> *Subject:* MDM Database Export Dear Komal, I was referred to you by [@Kesisoglou, Eleni|mailto:Eleni.Kesisoglou@pfizer.com]. I'm interested in obtaining an export via MDM that includes *approved speakers per country and their last briefing date.* Specifically, I require data for *all Adriatic countries,* including Slovenia, Croatia, Bosnia, and Serbia. Thank you in advance! Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]> *Sent:* Tuesday, July 23, 2024 11:53 AM *To:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]>; Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]> *Cc:* Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Hello dear Barbara, Since Mariem is on leave, I would like to inform you that we discussed your query along with our global team in our previous catch up and we concluded that MAPP Navigator can currently not provide any export that would contain approved speakers with expiration/renewal date. This export although could be made via MDM database. Kindly refer to [komal.mantri@pfizer.com|mailto:komal.mantri@pfizer.com] who has provided to us such an export for AfME two months ago. Even there although, despite the fact that we may see if an HCP is approved, we can see only his/her last briefing date and not the expiration date: !image001.png|thumbnail! In any case, I believe an extract like this for now would be a good start for your market so as to begin maintaining an approved speaker list till any future enhancement in MAPP Navigator reporting/exporting system. Best Regards, !image002.png|thumbnail!!image003.png|thumbnail! *From**:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Sent**:* Tuesday, July 23, 2024 12:34 PM *To**:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]> *Cc**:* Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject**:* RE: Update to Global Speaker Program Policy Hi, I wanted to follow-up on my previous email regarding Section 2.3 – can we generate a country-specific list of approved speakers from the MAPP Navigator system (e.g. export Excel)? Is it possible to view the approval date of each speaker and their expiration date for renewal within the MAPP Navigator system? Thanks in advance for your feedback! Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* Veberič, Barbara *Sent:* Wednesday, July 17, 2024 11:38 AM *To:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Hi, Very helpful. Thank you! Regarding Section 2.3 (Speakers – Approved List and Periodic Checks) – can we generate a country-specific list of approved speakers from the MAPP Navigator system (e.g. export Excel)? Is it possible to view the approval date of each speaker and their expiration date for renewal within the MAPP Navigator system? Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]> *Sent:* Wednesday, July 17, 2024 11:28 AM *To:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Hi Barbara. Sorry I missed your email please see below my answers below in green. Let me please if you need any further details Best Regards Mariem *From:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Sent:* Thursday, July 11, 2024 1:23 PM *To:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Hi, Thank you once again! I still need some clarification on policy sections 2.3 and 2.5 – please see below. Regarding Section 2.3 (Speakers – Approved List and Periodic Checks), I understand that our local Medical Affairs colleagues will maintain the updated list of qualified and approved speakers. However, I would like to know *who can assist our market in setting up a speaker lis**t.* {color:#70AD47}Not sure I I got well this time your question{color} {color:#70AD47}😊{color}{color:#70AD47} The approved speaker list is maintained in MDM (Navigator HCP database). As long as there are historical transactions with speakers approved, they will be automatically saved in MDM and will be expired after 1 year. You do not need to separately maintain a speaker list.{color} Additionally, concerning Section 2.5 (Speaker Materials and Content), the policy states that markets using the MAPP Navigator system should upload approved speaker program content and its respective medical approval into the system. My question is *whether MAPP Navigator can serve as the sole archive for speaker program content, or if we need to maintain a separate local archive in a centralized local repository.:* {color:#70AD47}Agreed MN can be a central repository for external created content and its approval. However, for internal core deck, it still needs to go through GCMA and it is governed by medical team{color} Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]> *Sent:* Thursday, July 11, 2024 11:41 AM *To:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Dear Barbara I am very pleased to assist ! Kindly note below my comments in Green & please don’t hesitate if you have further questions & clarifications. Best Regards | *{color:black} *Mariem Ben Abdallah*{color}*{color:black} EMEA Speaker Program & Policy operations Senior Manager{color} | | | | *{color:#0000C9} *Meetings, External Engagements & Travel (MEET)*{color}*{color:black} Your Journey, Our Priority!{color} | *From:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Sent:* Wednesday, July 10, 2024 9:20 AM *To:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Dear Mariem, Thank you for your feedback. I still have a few remaining questions—apologies for the back-and-forth. * Is Version #3 of the GSPP, last updated in June 2024, the final version of the policy that will be effective from September 15, 2024? {color:#70AD47}YES effective date for all update will be SEP 15th{color} * Could we arrange local training sessions for relevant colleagues on the updated GSPP before its effective date, for example in early September? {color:#70AD47}MEET regional speaker program team will set up meetings to go through the policy updates and operational requirement with market stakeholders in next few weeks. In between Please feel free to contact myself and Eleni cc’d above if you have any other questions before the meeting. Also Marjeta in case there is any insight from local compliance perspective.{color} Additionally, I have specific questions regarding the policy sections: * Section 2.3 Speakers – Approved List and Periodic Checks: Who can assist us in establishing and maintaining an approved list of speakers? {color:#70AD47}Medical Affairs colleague will be suuporting on that please refer to section 3 in Roles & Responsibilities as well in the policy as per the below screen shot{color} !image004.jpg|thumbnail! * {color:#70AD47} {color}{color:windowtext}Section 2.5 Speaker Materials and Content – Retention: Can we exclusively utilize the MAPP Navigator system for storing final versions of speaker program presentations and their corresponding medical approval emails? This would allow us to remove archives from our centralized local repositories as per the June 2024 version of the GSPP, which requires final, approved Speaker Program content to be uploaded into MAPP Navigator post-delivery, along with evidence of review and approval.{color} {color:#70AD47}This is the expectation from the policy : for Markets Using Mapp Navigator final, approved Speaker Program content must be uploaded in{color} Thanks again! Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]> *Sent:* Tuesday, July 9, 2024 3:20 PM *To:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Dear Barbara. Kindly see below my comments Let me know please if this clear for you. Regards Mariem *From:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Sent:* Tuesday, July 9, 2024 8:17 AM *To:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Hi, Thank you for clarifying. I also have a few additional questions: * Who can assist us with updating the local SOP if we choose to maintain it as a reference? {color:#2B9B62}as stated, the expectation is to remove the local SOP from Markets , All local requirements should have been transitioned to the Country Annex Portal ( CAP ) and any future updates should be made therein to respond to your question if you prefer keep it the Local CCL will be responsible for updating it in alignment with the global Policy : Local SOP should be as consistent as the CAP{color} * Will training on the updated version of the GSPP be available before its effective date? {color:#2B9B62}Global SPP Training including updates will be launched by the End of this year.{color} Can we obtain core slides for the updated GSPP to facilitate local-level training sessions? {color:#2B9B62}Please refer to the PPT attached in Global the communication - I am attaching also for your reference a different version of comparisons between the old policy language and the new language. It’s not every tiny change but includes the main updates that we made in the latest version. It’s not perfectly cleaned up, but hopefully will do the trick for now.{color} Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]> *Sent:* Monday, July 8, 2024 11:56 AM *To:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]>; Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* RE: Update to Global Speaker Program Policy Dear Barbara. Thank you for reaching out to us. Indeed, the update will be effective by September 15th, 2024, these updates should be reflected into the CAP of each Market ( Speaker Program Management section) ; if you may see in the update the expectation is to remove the local SOP & All local requirements should have been transitioned to the Country Annex Portal ( CAP ) and any future updates should be made therein unless the Market has a business reason to keep it as a reference hence in this case both local SOP & CAP must be accurate & consistent . We as Speaker Program Team are the owner of this policy and certainly will liase with you & [@Bojic Kek, Marjeta|mailto:Marjeta.BojicKek@pfizer.com] to make this update consistent & clear across the Market . ( you can refer to the section Roles & Responsibilities in Page 15 -17 Hope this clarifies your query , otherwise please let me know if you have further question happy to assist Best Regards | *{color:black} *Mariem Ben Abdallah*{color}*{color:black} EMEA Speaker Program & Policy operations Senior Manager{color} | | | | *{color:#0000C9} *Meetings, External Engagements & Travel (MEET)*{color}*{color:black} Your Journey, Our Priority!{color} | *From:* Veberič, Barbara <[Barbara.Veberic@pfizer.com|mailto:Barbara.Veberic@pfizer.com]> *Sent:* Friday, July 5, 2024 11:46 AM *To:* Ben Abdallah, Mariem <[Mariem.BenAbdallah@pfizer.com|mailto:Mariem.BenAbdallah@pfizer.com]>; Kesisoglou, Eleni <[Eleni.Kesisoglou@pfizer.com|mailto:Eleni.Kesisoglou@pfizer.com]> *Cc:* Bojic Kek, Marjeta <[Marjeta.BojicKek@pfizer.com|mailto:Marjeta.BojicKek@pfizer.com]> *Subject:* FW: Update to Global Speaker Program Policy Dear Colleagues, My name is Barbara Veberič, and I have recently assumed the role of Medical Quality Governance Manager for the Adriatic region, succeeding Andrej Babnik, who will retire on July 15th. Andrej currently oversees the local Speaker Program Policy SOP for the Adriatic region and its MAPP Country Annexes for Slovenia, Croatia, Serbia, Bosnia, and CBC. As I take on this responsibility, I will serve as the interim owner until the updated version comes into effect. According to recent communications, there is a planned transfer of ownership for GSPP and an update to the policy, scheduled to take effect on September 15th, 2024. *I am seeking clarification on how these changes will impact our markets, particularly regarding the transfer of ownership, updates to local SOPs aligned with global policies, and revisions to local country annexes.* Your guidance during this transition period would be greatly appreciated, and I kindly request to be kept informed of any developments moving forward. Thanks in advance! Best, Barbara *{color:#0000C9} *Barbara Veberič, MPharm*{color}* {color:#0000C9}Medical Quality Governance Manager (MQGM) Adriatic{color}{color:#0000C9}{color} {color:#0000C9}{color} *{color:#0000C7} *IDM Medical Affairs*{color}*{color:#0000C7}{color} {color:#0000C7}Pfizer Luxembourg SARL, Branch Office Ljubljana{color} {color:#0000C7}Letališka cesta 29a, 1000 Ljubljana, SIovenia{color} *{color:#0000C7} *M*{color}*{color:#0000C7}: +386 40 217 525{color} *{color:#0000C7} {color}* *{color:#A6A6A6} *CONFIDENTIALITY NOTICE*{color}*{color:#A6A6A6}: _This e-mail message from Pfizer Luxembourg SARL, Slovenia Branch Office (including all attachments) is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies. If you wish to report an adverse event, please contact_{color} [ _{color:#A6A6A6} _SVN.AEReporting@pfizer.com_{color}_|mailto:SVN.AEReporting@pfizer.com] _{color:#A6A6A6} _._{color}_ *From:* Global Speaker Program and Policy <[GlobalSpeakerProgramandPolicy@pfizer.com|mailto:GlobalSpeakerProgramandPolicy@pfizer.com]> *Sent:* Wednesday, 3 July 2024 21:14 *To:* No reply <[noreply-OnMessage@pfizer.com|mailto:noreply-OnMessage@pfizer.com]> *Subject:* Update to Global Speaker Program Policy Dear Colleagues. We hope all is well at your end. As you may be aware, over the past few months, the Compliance team, and the Global Business Services - Meetings, External Engagements, and Travel - Process Integration & Controls team (GBS MEET PI&C) have been working to transition the ownership of the Global Speaker Program Policy, which was previously managed by the Global Risk Lead within Compliance. In parallel, we received endorsement from the Commercial Quality & Risk Committee (CQRC) to build a team within the GBS MEET PI&C organization to support operationalization of speaker program requirements within markets across {color:black} the respective regions (EMEA, LATAM, and APAC).{color} The objective of this new team is to further streamline operations across markets while enhancing overall efficiency and strengthening risk management. We look forward to receiving your continued attention and support during this crucial period of transition as the team assumes their new responsibilities. Below is an overview of the GBS MEET PI&C team that will support the Global Policy and Process Oversight:{color:black}{color} | *Global Contacts* | ? Brian Badal (Sr. Director, Global MEET PI&C Lead) ? Huzefa Rangwala (Director, MEET PI&C and Global Speaker Program Policy Owner) | | *Regional Contacts* | *APAC :* * Katherine Yang (Sr. Manager - MEET PI&C APAC Regional Lead)* Li Peng Lin (Sr. Analyst - MEET PI&C APAC Region) | | *EMEA (excluding Spain and Portugal):* * Mariem Ben Abdallah (Sr. Manager - MEET PI&C EMEA Regional Lead) * Eleni Kesisoglou (Sr. Analyst - EMEA Region) | | *LATAM : and including Canada, Spain, and Portugal* * Andrea Villalobos (Director - MEET PI&C) * Norman Leandro (Sr. Manager - MEET LATAM Regional Lead) * Alejandra Perez (Sr. Analyst - LATAM Region) | Alison Page (Global Risk Lead for HCP Consultancies) will continue to partner and support the GBS MEET PI&C team in managing the Global Speaker Program Policy going forward. We have made updates to the Global Speaker Program Policy to incorporate updated roles & responsibilities of various functions associated with speaker programs, including the new responsibilities for GBS MEET PI&C, as well as to clarify certain policy requirements. The updated policy will become effective on *{color:#00B050} *September 15, 2024.*{color}* The updated policy and a summary of the recent updates are attached to this email. Please cascade this message to your team and other relevant colleagues, as needed. In the coming days, GBS MEET PI&C Regional teams will be reaching out to colleagues in the Markets to support the transition and will partner with market Compliance to update the requirements within the local Country Annex, as needed. Your cooperation and commitment to adapting these changes are greatly appreciated. If you have any questions or concerns, please feel free to reach out to the above mentioned contact points or to our mailbox at [GlobalSpeakerProgramandPolicy@pfizer.com|mailto:GlobalSpeakerProgramandPolicy@pfizer.com]. *Best regards,* *Brian Badal, GBS MEET PI&C Lead & Alison Page, Global Risk Lead*", "comment": "Thank you for the update. !image001.png|thumbnail! !image002.png|thumbnail!!image003.png|thumbnail! !image004.jpg|thumbnail!, mdm hub, please help me, MDM HUB please help me respond, MDM HUB can you respond please, MDM team, we need a status update", "labels": "mdm_escalation", "status": "Canceled", "assignee": "Anuskiewicz, Piotr", "updated": "2025-07-04T05:28:24.4-0400" } |